...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Avanafil for the treatment of erectile dysfunction.
【24h】

Avanafil for the treatment of erectile dysfunction.

机译：阿瓦那非治疗勃起功能障碍。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Erectile dysfunction is a prevalent condition afflicting millions of men worldwide and can have disastrous effects on a couple's quality of life. With the understanding of the physiology of erections and the discovery of cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5) inhibitors, therapy for erectile dysfunction was revolutionized, and this class of medication became the first-line treatment option for this widespread condition. Despite the ease of use, efficacy and tolerability of the available PDE5 inhibitors, many men discontinue their use, usually related to lack of efficacy or development of adverse events. As such, research into the development of other medications within this drug class is extensive. Avanafil is a novel PDE5 inhibitor with favorable pharmacokinetic and pharmacodynamic profiles with good tolerability and limited adverse events. It was recently approved and launched in Korea, and is currently under review by the U.S. Food and Drug Administration. Its efficacy and purported role in the treatment for erectile dysfunction are reviewed here.
机译：勃起功能障碍是一种普遍的疾病，困扰着全世界成千上万的男人，并且可能对夫妻的生活质量造成灾难性的影响。随着对勃起生理的了解和cGMP特异的3'，5'-环磷酸二酯酶（PDE5）抑制剂的发现，勃起功能障碍的治疗方法发生了革命性的变化，这类药物成为这种广泛使用的一线治疗选择健康）状况。尽管可用的PDE5抑制剂易于使用，具有疗效和耐受性，但许多男性仍停止使用，通常与缺乏功效或不良事件发展有关。因此，对该类药物中其他药物的开发进行了广泛的研究。 Avanafil是一种新型PDE5抑制剂，具有良好的药代动力学和药效学特征，具有良好的耐受性和有限的不良事件。它最近在韩国获得批准并发布，目前正在接受美国食品药品监督管理局的审查。本文综述了其在勃起功能障碍治疗中的功效和作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号